NXS — Next Science Income Statement
0.000.00%
- AU$29.22m
- AU$30.50m
- $22.82m
- 31
- 31
- 20
- 17
Annual income statement for Next Science, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.44 | 8.95 | 11.7 | 22.2 | 22.8 |
Cost of Revenue | |||||
Gross Profit | 2.92 | 6.94 | 9.15 | 16.2 | 18.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 15.6 | 18.4 | 24.4 | 37.7 | 33.1 |
Operating Profit | -12.2 | -9.48 | -12.7 | -15.6 | -10.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -11.9 | -9.35 | -12.7 | -16.3 | -10.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -11.9 | -9.35 | -12.7 | -16.3 | -10.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -11.9 | -9.35 | -12.7 | -16.3 | -10.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -11.9 | -9.35 | -12.7 | -16.3 | -10.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.065 | -0.048 | -0.06 | -0.071 | -0.036 |